Training OPportunites in Translational Imaging Education and Research (TOP-TIER)

项目摘要 TOP-TIER（翻译成像教育和研究中的培训机会）是一名临床科学家 圣路易斯华盛顿大学（WU）的博士后培训计划旨在 为受训者提供严格的转化成像研究的指导。目标 是准备居民和学员的职业生涯作为成功的独立调查员， 最终成为各自领域的领导者，开发成像技术和应用， 人类受试者和影响医疗保健。精准医学是一种疾病治疗方法， 预防考虑到基因、环境和生活方式的个体差异。发展 患者特异性生物标志物成像的方法，以指导和监测患者特异性治疗， 需要推进精准医疗。此外，训练有素的劳动力是利用新技术的关键。 机器学习和人工智能的发展，可以应用于各个学科， 包括靶向分子成像、光声和磁共振成像（MRI）， 数据采集、图像处理和诊断。这种成像技术的进步是跨学科的， 跨越物理、生物和数据科学的技术创新。这些研究始于 在动物疾病模型中使用基于靶向病理学的成像进行临床前机制研究，以及 然后扩展到人体实验人体研究包括安全性测试和食品药品监督管理局 FDA的研究性新药（IND）和器械豁免（IDE）程序。最终 目标是使研究创新广泛提供给公众和整个执业医疗 社区虽然这种“从板凳到床边”的过程受到了广泛的赞誉，但仍然存在一个问题， 医学成像研究界关于如何将临床前研究纳入 以及如何将这些创新推向大众。此外，临床科学家-居民和 研究员-往往缺乏了解导航研究监管要求以及 知识库，以了解或执行临床前研究，将告知创新机制。 在此次T32续订中，我们优化了培训，以提供支持性指导团队，并涵盖技术 进步，研究的严谨性，以及资助提交的实际方面，以更好地准备未来的成像 科学家应对影响医疗保健的科学挑战。

PROJECT SUMMARY TOP-TIER (Training OPportunities in Translational Imaging Education and Research) is a clinician scientist post-doctoral training program at Washington University (WU) in St. Louis designed with the purpose of providing trainees with instruction in the performance of rigorous translational imaging research. The goal is to prepare resident and fellow trainees for careers as successful independent investigators and to ultimately become leaders in their field, developing imaging techniques and applications that translate into human subjects and impact healthcare. Precision Medicine is an approach to disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. Development of methods of patient-specific biomarker imaging to guide and monitor patient-specific therapies will be needed to advance Precision Medicine. Moreover, a trained workforce is key to taking advantage of new developments in machine learning and artificial intelligence which can be applied across disciplines, to include targeted molecular imaging, photoacoustics, and magnetic resonance imaging (MRI) in terms of data acquisition, image processing, and diagnosis. Such imaging advances are interdisciplinary with technology innovations crossing the physical, biological, and data sciences. These studies start with preclinical mechanistic inquiries using targeted pathology-based imaging in animal disease models, and then expand into human subjects. Human studies include safety testing and the Food and Drug Administration’s (FDA) Investigational New Drug (IND) and Device Exemption (IDE) process. The ultimate goal is to make research innovations widely available to the public and the entire practicing medical community. Although this “bench-to-bedside” process has been widely acclaimed, there remains a knowledge gap in the medical imaging research community as to how to take preclinical research into humans, and how to then take these innovations to the public. Moreover, clinical scientists – residents and fellows – often lack the understanding to navigate research regulatory requirements as well as the knowledge base to understand or perform preclinical research that will inform the mechanism of innovation. In this T32 renewal, we have optimized training to provide supportive Mentoring Teams and cover technical advances, research rigor, and the practical aspects of grant submission to better prepare future imaging scientists for the challenges of performing science which impacts healthcare.